Literature DB >> 10836284

LSD-induced hallucinogen persisting perception disorder treatment with clonidine: an open pilot study.

A G Lerner1, M Gelkopf, I Oyffe, B Finkel, S Katz, M Sigal, A Weizman.   

Abstract

A pilot open study was conducted in order to evaluate the efficacy of clonidine in the treatment of LSD-induced hallucinogen persisting perception disorder (HPPD). Eight patients fulfilled entrance criteria. All complained of HPPD for at least 3 months and were drug free at least 3 months. They received fixed low doses of clonidine, 0.025 mg, three times a day for 2 months. They were evaluated by the Clinical Global Impression Scale (CGI) and a self-report scale on the severity of symptoms (graded 0-5). Patients scored an average of 5.25 (SD = 0.46) on the CGI and 4 on the self-report scale at baseline, indicating marked psychopathology. One patient dropped out at week 3 and a second patient dropped out at week 5. Of the six patients remaining at the end of 2 months, the average CGI score was 2.5 (SD = 0.55) and the self-report scale score was 2, indicating mild symptomatology. LSD-related flashbacks associated with excessive sympathetic nervous activity may be alleviated with clonidine in some patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10836284     DOI: 10.1097/00004850-200015010-00005

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  4 in total

1.  Hallucinogen-persisting perception disorder.

Authors:  Leo Hermle; Melanie Simon; Martin Ruchsow; Martin Geppert
Journal:  Ther Adv Psychopharmacol       Date:  2012-10

Review 2.  The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review.

Authors:  Laura Orsolini; Gabriele Duccio Papanti; Domenico De Berardis; Amira Guirguis; John Martin Corkery; Fabrizio Schifano
Journal:  Front Psychiatry       Date:  2017-11-20       Impact factor: 4.157

Review 3.  Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives.

Authors:  Giovanni Martinotti; Rita Santacroce; Mauro Pettorruso; Chiara Montemitro; Maria Chiara Spano; Marco Lorusso; Massimo di Giannantonio; Arturo G Lerner
Journal:  Brain Sci       Date:  2018-03-16

4.  Pathological Delta Oscillations in Hallucinogen Persisting Perception Disorder: A Case Report.

Authors:  David Haslacher; Nikolina Novkovic; Maria Buthut; Andreas Heinz; Surjo R Soekadar
Journal:  Front Psychiatry       Date:  2022-03-24       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.